Charles G Drake
#110,908
Most Influential Person Now
Researcher
Charles G Drake's AcademicInfluence.com Rankings
Charles G Drakeengineering Degrees
Engineering
#3203
World Rank
#4242
Historical Rank
Electrical Engineering
#684
World Rank
#747
Historical Rank
Charles G Drakecomputer-science Degrees
Computer Science
#4188
World Rank
#4406
Historical Rank
Computational Linguistics
#355
World Rank
#360
Historical Rank
Machine Learning
#745
World Rank
#755
Historical Rank
Artificial Intelligence
#952
World Rank
#969
Historical Rank
Download Badge
Engineering Computer Science
Charles G Drake's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
- Bachelors Computer Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Charles G Drake Influential?
(Suggest an Edit or Addition)Charles G Drake's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (2012) (10640)
- Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. (2012) (6726)
- Immune checkpoint blockade: a common denominator approach to cancer therapy. (2015) (3000)
- Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. (2010) (2647)
- A draft map of the human proteome (2014) (1901)
- Inflammation in prostate carcinogenesis (2007) (1570)
- Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. (2012) (1203)
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. (2014) (1201)
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. (2012) (1192)
- Role of LAG-3 in regulatory T cells. (2004) (1110)
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma (2018) (772)
- Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. (2013) (735)
- Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. (2013) (665)
- Mechanisms of immune evasion by tumors. (2006) (646)
- Cutting Edge: An In Vivo Requirement for STAT3 Signaling in TH17 Development and TH17-Dependent Autoimmunity1 (2007) (582)
- Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. (2015) (563)
- LAG3 (CD223) as a cancer immunotherapy target (2017) (545)
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody (2012) (502)
- Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen (2014) (484)
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. (2017) (477)
- A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. (2008) (465)
- Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. (2009) (454)
- Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. (2018) (452)
- LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. (2007) (445)
- Egr-2 and Egr-3 are negative regulators of T cell activation (2005) (431)
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma (2011) (419)
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. (2015) (400)
- Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing (2008) (388)
- Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer (2014) (377)
- The composition and signaling of the IL-35 receptor are unconventional (2012) (372)
- Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? (2019) (357)
- Prostate cancer as a model for tumour immunotherapy (2010) (328)
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. (2019) (326)
- Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas (2016) (319)
- Eos Mediates Foxp3-Dependent Gene Silencing in CD4+ Regulatory T Cells (2009) (306)
- Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer (2016) (300)
- Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. (2014) (300)
- Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. (2006) (298)
- Prostate cancer (2016) (288)
- Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. (2005) (286)
- Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. (2020) (260)
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (2015) (256)
- LAG-3 in Cancer Immunotherapy. (2011) (253)
- Bacteriolytic therapy can generate a potent immune response against experimental tumors. (2004) (250)
- Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy (2013) (246)
- Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. (2016) (230)
- Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+ (2009) (226)
- Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model (2014) (219)
- Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells1 (2009) (216)
- A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. (2010) (213)
- Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial (2014) (212)
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma (2016) (208)
- Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. (2007) (204)
- Tc17 CD8 T Cells: Functional Plasticity and Subset Diversity1 (2009) (198)
- LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis1 (2009) (184)
- Genetic analysis of the NZB contribution to lupus-like autoimmune disease in (NZB x NZW)F1 mice. (1994) (184)
- Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy (2018) (165)
- Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. (2009) (156)
- Analysis of the New Zealand Black contribution to lupus-like renal disease. Multiple genes that operate in a threshold manner. (1995) (154)
- Phenotypic and Functional Properties of Helios+ Regulatory T Cells (2012) (152)
- Paucity of PD-L1 Expression in Prostate Cancer: Innate and Adaptive Immune Resistance (2015) (148)
- Glycoprotein 96 Can Chaperone Both MHC Class I- and Class II-Restricted Epitopes for In Vivo Presentation, but Selectively Primes CD8+ T Cell Effector Function 1 (2004) (146)
- Control of multiple autoantibodies linked with a lupus nephritis susceptibility locus in New Zealand black mice. (1997) (145)
- Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T cell immunity to tumor antigens (2019) (143)
- Immunotherapy earns its spot in the ranks of cancer therapy (2012) (143)
- Combination immunotherapy approaches. (2012) (141)
- B and T Lymphocyte Attenuator Exhibits Structural and Expression Polymorphisms and Is Highly Induced in Anergic CD4+ T Cells 1 (2005) (141)
- Effect of genetic background on the contribution of New Zealand black loci to autoimmune lupus nephritis. (1996) (141)
- Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors (2016) (135)
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer (2018) (135)
- Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment (2017) (133)
- Biomarkers for immunotherapy in bladder cancer: a moving target (2017) (133)
- Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. (2015) (132)
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment (2017) (131)
- Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. (2018) (129)
- Genetic linkage of IgG autoantibody production in relation to lupus nephritis in New Zealand hybrid mice. (1996) (126)
- Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3 (2011) (124)
- The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder (2016) (122)
- Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer (2014) (120)
- Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer (2018) (118)
- Consensus nomenclature for CD8+ T cell phenotypes in cancer (2015) (118)
- Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research (2011) (116)
- Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. (2012) (115)
- Association of IL10 and Other immune response‐ and obesity‐related genes with prostate cancer in CLUE II (2009) (114)
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (110)
- Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome (2015) (110)
- The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma (2016) (110)
- Lymphocyte Activation Gene 3 (LAG-3) Modulates the Ability of CD4 T-cells to Be Suppressed In Vivo (2014) (110)
- Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis (2016) (106)
- Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. (2018) (106)
- Inhibitors of the PD-1 Pathway in Tumor Therapy (2018) (98)
- Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. (2010) (94)
- Expression of LAG‐3 and efficacy of combination treatment with anti‐LAG‐3 and anti‐PD‐1 monoclonal antibodies in glioblastoma (2018) (86)
- Immunotherapy for Brain Cancer: Recent Progress and Future Promise (2014) (85)
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (85)
- KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). (2018) (83)
- Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce (2020) (83)
- A Subset of TREM2+ Dermal Macrophages Secretes Oncostatin M to Maintain Hair Follicle Stem Cell Quiescence and Inhibit Hair Growth. (2019) (83)
- B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly induced in anergic CD4+ T cells (2005) (82)
- Radiotherapy augments the immune response to prostate cancer in a time‐dependent manner (2008) (82)
- A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination (2015) (81)
- CD4+ T Cells Pass Through an Effector Phase During the Process of In Vivo Tolerance Induction (2003) (79)
- STAT3 Signaling in CD4+ T Cells Is Critical for the Pathogenesis of Chronic Sclerodermatous Graft-Versus-Host Disease in a Murine Model (2009) (78)
- The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response (2020) (77)
- Prostate carcinogenesis: inflammatory storms (2020) (77)
- Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages (2021) (77)
- A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression (2015) (76)
- Quantitative Analysis of Immune Infiltrates in Primary Melanoma (2018) (75)
- Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. (2020) (74)
- Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer (2013) (74)
- Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials (2019) (72)
- Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. (2009) (72)
- Genetic Contributions to Lupus‐like Disease in (NZB×NZW)F1 Mice (1995) (70)
- Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. (2013) (70)
- Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses (2013) (68)
- Primer on tumor immunology and cancer immunotherapy (2013) (68)
- Potential Role of Decoy B7-H4 in the Pathogenesis of Rheumatoid Arthritis: A Mouse Model Informed by Clinical Data (2009) (67)
- Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up. (2013) (67)
- Immunotherapy for prostate cancer: recent developments and future challenges (2014) (65)
- Differential subcellular localization of the regulatory T‐cell protein LAG‐3 and the coreceptor CD4 (2010) (64)
- Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. (2014) (63)
- A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone (2020) (62)
- A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts (2017) (61)
- Kidney Cancer: An Overview of Current Therapeutic Approaches. (2020) (61)
- Sustained CD4+ T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide (2014) (60)
- Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 (2020) (60)
- New Strategies in Bladder Cancer: A Second Coming for Immunotherapy (2015) (59)
- A phased strategy to differentiate human CD14+monocytes into classically and alternatively activated macrophages and dendritic cells. (2016) (58)
- Assessing oncologic benefit in clinical trials of immunotherapy agents. (2010) (57)
- Myeloid‐derived cells in prostate cancer progression: phenotype and prospective therapies (2017) (56)
- Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial (2016) (56)
- Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. (2015) (56)
- Expression profile and in vitro blockade of programmed death‐1 in human papillomavirus–negative head and neck squamous cell carcinoma (2015) (54)
- Evidence for polyclonal T cell activation in murine models of systemic lupus erythematosus. (1994) (53)
- Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells (2006) (53)
- Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination (2015) (52)
- Variation in IL10 and Other Genes Involved in the Immune Response and in Oxidation and Prostate Cancer Recurrence (2012) (52)
- Prostate Cancer Immunotherapy (2011) (51)
- Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern (2017) (51)
- Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies (2008) (51)
- Contributions of Ea(z) and Eb(z) MHC genes to lupus susceptibility in New Zealand mice. (1998) (51)
- Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. (2016) (50)
- Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer (2017) (50)
- Current status of immunological therapies for prostate cancer (2010) (50)
- Combination of dual immune checkpoint inhibition (ICI) with stereotactic radiation (SBRT) in metastatic renal cell carcinoma (mRCC) (RADVAX RCC). (2020) (48)
- T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer (2020) (46)
- A 2 A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells (2007) (46)
- Cutting Edge: TCR-Induced NAB2 Enhances T Cell Function by Coactivating IL-2 Transcription1 (2006) (46)
- PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice. (2020) (46)
- Lenalidomide in Nonmetastatic Biochemically Relapsed Prostate Cancer: Results of a Phase I/II Double-Blinded, Randomized Study (2010) (46)
- Cyclophosphamide Unmasks an Antimetastatic Effect of Local Tumor Cryoablation (2009) (46)
- The Immunobiology of Kidney Cancer. (2018) (46)
- Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy (2014) (46)
- Superantigens: Biology, immunology, and potential role in disease (1992) (45)
- Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma (2015) (45)
- Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition (2019) (45)
- Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks (2018) (45)
- Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer (2017) (44)
- TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors (2018) (44)
- A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. (2020) (43)
- A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells (2015) (41)
- A multi-omic analysis of human naïve CD4+ T cells (2015) (40)
- Tumor Recognition and Self-Recognition Induce Distinct Transcriptional Profiles in Antigen-Specific CD4 T Cells 1 (2009) (40)
- Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies (2010) (39)
- PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond (2014) (38)
- Immune Signatures Predict Prognosis in Localized Cancer (2010) (38)
- Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260). (2020) (38)
- Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. (2016) (37)
- Immunotherapy for prostate cancer: walk, don't run. (2009) (37)
- Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression (2019) (36)
- Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses (2020) (36)
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma (2016) (36)
- Update: Immunological Strategies for Prostate Cancer (2010) (35)
- Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial (2017) (35)
- Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial (2022) (35)
- Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T (2020) (35)
- A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies. (2011) (34)
- Combining Intra-Tumoral Treg Depletion with Androgen Deprivation Therapy (ADT): Pre-Clinical Activity in the Myc-CaP Model (2017) (34)
- Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml−1, normal DRE and negative for prostate cancer (2015) (34)
- Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (2016) (33)
- Pembrolizumab (Pembro) plus enzalutamide (Enz) in metastatic castration resistant prostate cancer (mCRPC): Extended follow up. (2018) (33)
- PD-L1 expression in medulloblastoma: an evaluation by subgroup (2018) (33)
- Genitourinary tumors, non-prostate (2012) (31)
- A Pilot Trial of Pembrolizumab plus Prostatic Cryotherapy for Men with Newly Diagnosed Oligometastatic Hormone-Sensitive Prostate Cancer (2019) (31)
- Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas (2015) (31)
- Non-parametric, hypothesis-based analysis of microarrays for comparison of several phenotypes (2004) (31)
- 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1 (2019) (30)
- Resolution of infection promotes a state of dormancy and long survival of CD4 memory T cells (2010) (30)
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. (2018) (30)
- Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'? (2014) (29)
- Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy (2016) (29)
- The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? (2019) (29)
- First evidence of significant clinical activity of PD-1 inhibitors in metastatic, castration resistant prostate cancer (mCRPC) (2016) (29)
- Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. (2015) (29)
- Allogeneic versus autologous blood transfusion and survival after radical prostatectomy (CME) (2014) (29)
- Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy. (2018) (29)
- Circulating Beta-2 Microglobulin and Risk of Cancer: The Atherosclerosis Risk in Communities Study (ARIC) (2016) (28)
- Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) (2020) (28)
- Cooperation of loss of NKX3.1 and inflammation in prostate cancer initiation (2018) (27)
- Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. (2009) (27)
- A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer (2020) (27)
- Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer (2018) (27)
- De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute (2016) (27)
- Genetic and immunological mechanisms in the pathogenesis of systemic lupus erythematosus. (1992) (27)
- Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial (2015) (27)
- An empirical antigen selection method identifies neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth. (2021) (26)
- Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting (2020) (26)
- Cancer Immunotherapy Highlights from the 2014 ASCO Meeting (2014) (25)
- Immunotherapy for Prostate Cancer. (2018) (25)
- A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer. (2016) (24)
- Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. (2012) (24)
- Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC). (2017) (24)
- Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy (2012) (23)
- Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial (2015) (23)
- Immunostimulatory cancer-associated fibroblast subpopulations can predict immunotherapy response in head and neck cancer. (2022) (22)
- Consequences of interleukin 1β‐triggered chronic inflammation in the mouse prostate gland: Altered architecture associated with prolonged CD4+ infiltration mimics human proliferative inflammatory atrophy (2019) (22)
- Tumor immunology--towards a paradigm of reciprocal research. (2002) (22)
- Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells (2017) (21)
- Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival (2018) (21)
- A Peripheral Circulating TH1 Cytokine Profile Is Inversely Associated with Prostate Cancer Risk in CLUE II (2014) (21)
- IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to Immunotherapy. (2018) (21)
- Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial (2021) (21)
- Absence of host NF-κB p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization (2018) (20)
- Update on Prostate Cancer Vaccines (2011) (20)
- Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research. (2013) (20)
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2023) (20)
- Asthma and risk of lethal prostate cancer in the Health Professionals Follow‐Up Study (2015) (20)
- Current status of immunological approaches for the treatment of prostate cancer (2012) (19)
- Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial (2017) (19)
- Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. (2021) (19)
- Radiation-Induced Immune Modulation (2011) (19)
- Microenvironment and Immunology Evidence for a Role of the PD-1 : PD-L 1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma (2013) (19)
- A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results. (2013) (19)
- Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC). (2014) (18)
- Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select. (2016) (18)
- Immune checkpoint inhibitors: a new frontier in bladder cancer (2015) (17)
- Combined Immune Checkpoint Blockade. (2015) (17)
- Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model. (2013) (17)
- Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond (2018) (17)
- Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer (2021) (16)
- Abstract CT026: Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors (2019) (16)
- Lenalidomide modulates IL‐8 and anti‐prostate antibody levels in men with biochemically recurrent prostate cancer (2012) (16)
- Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors (2020) (16)
- Epithelial architectural destruction is necessary for bone marrow derived cell contribution to regenerating prostate epithelium. (2006) (16)
- Anti-IL-10–mediated Enhancement of Antitumor Efficacy of a Dendritic Cell–targeting MIP3&agr;-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons (2018) (16)
- Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC). (2012) (16)
- Subverting the B7-H1/PD-1 Pathway in Advanced Melanoma and Kidney Cancer (2014) (15)
- Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC) (2015) (15)
- Molecular Pathways: Co-Expression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy (2013) (14)
- PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143). (2019) (14)
- Association of immune response- and obesity-related genes with prostate cancer in CLUE II (2007) (13)
- Tumor immune microenvironment in non-muscle invasive urothelial carcinoma of bladder. (2019) (13)
- Hypomethylation, endogenous retrovirus expression, and interferon signaling in testicular germ cell tumors (2018) (13)
- Summary from the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. (2020) (13)
- Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. (2012) (13)
- Melanoma and immunotherapy bridge 2015 (2016) (13)
- Recent advances in immunotherapy for kidney cancer. (2016) (13)
- Strain‐specific induction of experimental autoimmune prostatitis (EAP) in mice (2013) (13)
- Systemic depletion of lymphocytes following focal radiation to the brain in a murine model (2018) (13)
- Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. (2007) (12)
- CD38 in Advanced Prostate Cancers (2021) (12)
- A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC). (2017) (12)
- Racial differences in prostate inflammation: results from the REDUCE study (2016) (12)
- A Phase 1 Trial of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin for the Treatment of Non-muscle Invasive BCG Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder. (2020) (12)
- Immunotherapy for prostate cancer: an emerging treatment modality. (2010) (12)
- Tc 17 CD 8 T Cells : Functional Plasticity and Subset Diversity 1 (2017) (12)
- Cytoreductive nephrectomy for metastatic renal cell carcinoma, the ultimate urologic ‘Choosing Wisely’ campaign: a narrative review (2020) (11)
- A role for paracrine interleukin‐6 signaling in the tumor microenvironment in prostate tumor growth (2018) (11)
- The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas. (2017) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016 (2017) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC). (2013) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Differential Immune Modulation With Carbon-Ion Versus Photon Therapy. (2020) (10)
- A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). (2014) (10)
- Combinatorial Immunotherapy (2012) (10)
- Clinical, pathologic, and genomic profiles of exceptional responders to anti−PD1 therapy in renal cell carcinoma. (2016) (10)
- Impact of baseline serum IL‐8 on metastatic hormone‐sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805) (2020) (10)
- Telemedicine in management of genitourinary malignancies: Patient and physician perspectives. (2021) (10)
- T cell regulation (1995) (10)
- Antigen spread and survival with sipuleucel-T in patients with advanced prostate cancer. (2014) (10)
- Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC): An updated analysis. (2013) (10)
- Immune response from STRIDE, a randomized, phase 2, open label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC). (2015) (10)
- Optimizing the management of castration‐resistant prostate cancer patients: A practical guide for clinicians (2020) (9)
- Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer. (2018) (9)
- A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D). (2011) (9)
- 763PDUPDATED OVERALL SURVIVAL (OS) FROM THE PHASE 3 TRIAL, CA184-043: IPILIMUMAB (IPI) VS PLACEBO (PBO) IN PATIENTS WITH POST-DOCETAXEL METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). (2014) (9)
- Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors. (2013) (9)
- A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide. (2019) (9)
- Erratum: Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (Annals of Oncology (2015) 26(8) (1589–1604), (S0923753419318691), (10.1093/annonc/mdv257)) (2019) (9)
- Does Prophylactic Nodal Irradiation Inhibit Potential Synergy Between Radiation Therapy and Immunotherapy (2016) (9)
- A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients (NCT02740985). (2020) (8)
- Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model (2017) (8)
- Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP). (2017) (8)
- Immune responses and clinical outcomes in STAND, a randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) after local therapy failure. (2015) (8)
- Immunotherapy for metastatic prostate cancer. (2008) (8)
- Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD (2019) (8)
- Anti‐tumor effects of endogenous prostate cancer‐specific CD8 T cells in a murine TCR transgenic model (2012) (8)
- A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC). (2017) (8)
- Microenvironment and Immunology Immune InhibitoryMolecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape (2012) (8)
- Harnessing the PD-1 Pathway in Renal Cell Carcinoma: Current Evidence and Future Directions (2014) (7)
- A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. (2020) (7)
- Antigen-specific immune responses through 24 months in the STAND trial: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC). (2015) (7)
- A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. (2019) (7)
- Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer (2019) (7)
- Role of Radiation Therapy in Inducing Antigen Specific Antitumor Immune Responses When Combined With Anti-PD1 Checkpoint Blockade: Mechanism and Clinical Implications (2014) (7)
- 1051PDIMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN PREVIOUSLY TREATED AND UNTREATED METASTATIC RENAL CELL CARCINOMA (MRCC): BIOMARKER-BASED RESULTS FROM A RANDOMIZED CLINICAL TRIAL. (2014) (7)
- Basic overview of current immunotherapy approaches in urologic malignancy. (2006) (7)
- Infectious complications in transfused patients after radical cystectomy. (2016) (6)
- Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer. (2019) (6)
- Peripheral Zone Inflammation Is Not Strongly Associated With Lower Urinary Tract Symptom Incidence and Progression in the Placebo Arm of the Prostate Cancer Prevention Trial (2016) (6)
- Overall survival and immune responses with sipuleucel-T and enzalutamide: STRIDE study. (2018) (6)
- Randomized phase II study of sipuleucel-T (SipT) with or without radium-223 (Ra223) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC). (2020) (6)
- TGM4: an immunogenic prostate-restricted antigen (2021) (6)
- Phase 1b/2 study of nivolumab in combination with an anti–IL-8 monoclonal antibody, BMS-986253, in a biomarker-enriched population of patients with advanced cancer. (2018) (6)
- Characterization of immune-related adverse events (irAEs) in a phase 3 trial of ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel mCRPC. (2014) (6)
- Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. (2017) (6)
- Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors (2022) (6)
- 774PSTRIDE, A RANDOMIZED, PHASE 2, OPEN-LABEL STUDY OF SIPULEUCEL-T WITH CONCURRENT VS SEQUENTIAL ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC). (2014) (6)
- Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial (2020) (6)
- Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward (2017) (6)
- Molecular imaging for cancer immunotherapy (2020) (6)
- PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). (2019) (6)
- The potential role of antigen spread in immunotherapy for prostate cancer. (2014) (6)
- Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy (2020) (6)
- Design of an open-label randomized phase II trial examining the effect of sequencing of sipuleucel-T and androgen deprivation therapy (ADT) on immune markers in prostate cancer patients with a rising prostate specific antigen (PSA) after primary therapy. (2011) (6)
- Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial (2016) (6)
- An IL‐2 proaerolysin fusion toxin that selectively eliminates regulatory t cells to enhance antitumor immune response (2019) (5)
- Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. (2012) (5)
- Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. (2021) (5)
- Longitudinal Immune Profiling Reveals Unique Myeloid and T-cell Phenotypes Associated with Spontaneous Immunoediting in a Prostate Tumor Model (2021) (5)
- Analysis of Circulating Immune Biomarkers by Race in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Sipuleucel-T (2021) (5)
- Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma (2015) (5)
- Transcriptional profiling of tumor associated macrophages in human renal cell carcinoma reveals significant heterogeneity and opportunity for immunomodulation. (2020) (5)
- 2526 Immune responses and clinical data from STRIDE, a randomized, phase 2, open label study of sipuleucel-T with concurrent vs sequential enzalutamide administration in metastatic castrationresistant prostate cancer (2015) (4)
- A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer. (2020) (4)
- Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. (2020) (4)
- A phase I/Ib, open-label, dose-finding study to evaluate safety, pharmacodynamics, and efficacy of pembrolizumab (MK-3475) in combination with vorinostat in patients with advanced renal or urothelial cell carcinoma. (2016) (4)
- Personalized viral-based prime/boost immunotherapy targeting patient-specific or shared neoantigens: Immunogenicity, safety, and efficacy results from two ongoing phase I studies. (2020) (4)
- Reply: Regulatory T cells—an important target for cancer immunotherapy (2014) (4)
- B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. (2022) (4)
- Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens (2020) (4)
- Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Previously Treated, Metastatic Renal Cell Carcinoma (MRCC) (2012) (4)
- CA184-043: A randomized, double-blind, phase III trial comparing ipilimumab versus placebo following a single dose of radiotherapy (RT) in patients (pts) with castration-resistant prostate cancer (CRPC) who have received prior treatment with docetaxel (D). (2012) (4)
- PD-1:PD-L1(B7-H1) pathway in adaptive resistance: A novel mechanism for tumor immune escape in human papillomavirus-related head and neck cancers. (2012) (3)
- A retrospective analysis of the effect of time from diagnosis to cystectomy on survival in patients with muscle-invasive bladder cancer receiving neoadjuvant chemotherapy. (2015) (3)
- PD27-04 SIPULEUCEL-T-INDUCED ANTIGEN SPREAD: IMMUNE RESPONSE TO PROSTATE-SPECIFIC ANTIGEN CORRELATES WITH IMPROVED OVERALL SURVIVAL (2014) (3)
- Cyto-KIK: A phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib). (2021) (3)
- PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). (2019) (3)
- 690TiP A phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; CheckMate 7DX) (2020) (3)
- Chronic In fl ammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial (2014) (3)
- 980 A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC): Immune results with a focus on humoral responses (2014) (3)
- BCG invokes superior STING‐mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer (2021) (3)
- Expression of neuropilin-1 on in vivo induced regulatory T cells (2013) (3)
- Mechanisms of Immune Modulation by Radiation. (2021) (3)
- A randomized double blind phase I-II study to determine the tolerability/efficacy of two different doses of lenalidomide (L), CC- 5013, in biochemically relapsed (BR) prostate cancer (PC) patients (pts) (M0) after local treatment (LT). (2009) (3)
- Erratum: Egr-2 and Egr-3 are negative regulators of T cell activation (2005) (3)
- An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD). (2018) (3)
- Immunotherapy for Prostate Cancer: An Evolving Landscape (2018) (3)
- Adoptive transfer of IL‐4 reprogrammed Tc17 cells elicits anti‐tumour immunity through functional plasticity (2022) (3)
- MP43-14 A PHASE 1 TRIAL OF INTRAVESICAL CABAZITAXEL, GEMCITABINE, AND CISPLATIN (CGC) FOR THE TREATMENT OF NON-MUSCLE INVASIVE BCG UNRESPONSIVE UROTHELIAL CARCINOMA OF THE BLADDER (2019) (3)
- A randomized phase Ib/II study of nivolumab with or without BMS-986253 in combination with a short course of ADT in men with castration-sensitive prostate cancer (MAGIC-8). (2019) (3)
- Combined next generation sequencing and flow cytometry analysis of an anti-PD-L1 partial responder over time: An exploration into mechanisms of PD-L1 activity and resistance (2017) (2)
- Combining Anti-PD-1 (B7-H1) Immunotherapy with Stereotactic Radiosurgery in a Mouse Orthotopic Glioblastoma Model (2011) (2)
- Changes in circulating lymphocyte counts and tumor-infiltrating lymphocyte subpopulations among patients receiving endorectal brachytherapy for rectal adenocarcinoma. (2014) (2)
- Current immunotherapeutic strategies in prostate cancer. (2007) (2)
- 775PA RANDOMIZED PHASE 2 STUDY EVALUATING OPTIMAL SEQUENCING OF SIPULEUCEL-T (SIP-T) AND ANDROGEN DEPRIVATION THERAPY (ADT) IN BIOCHEMICALLY-RECURRENT PROSTATE CANCER (BRPC): VARIABLES THAT CORRELATE WITH IMMUNE RESPONSE. (2014) (2)
- Dissecting the immune infiltrate induced by ADT and PD-1 blockade in men with metastatic hormone-sensitive prostate cancer using single-cell RNA-sequencing. (2020) (2)
- First Results of Phase I/II Studies Evaluating Viral Vector-Based Heterologous Prime/Boost Immunotherapy Against Predicted HLA Class I Neoantigens Demonstrate CD8 T Cell Responses In Patients with Advanced Cancers (2019) (2)
- A phase II study of rapid cycling high dose testosterone (Bipolar Androgen Therapy) in men with metastatic castrate-resistant prostate cancer (mCRPC) resistant to abiraterone and/or enzalutamide (2016) (2)
- A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. (2023) (2)
- Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC) (2015) (2)
- Preclinical development of combination therapy targeting the dominant cytokine interleukin-1β for renal cell carcinoma. (2019) (2)
- Blocking the regulatory T cell molecule LAG-3 augments in vivo anti-tumor immunity in an autochthonous model of prostate cancer. (2006) (2)
- 627P Phase II neoadjuvant trial of the anti–B7-H3 antibody, enoblituzumab, in men with localized prostate cancer: Safety, efficacy and immune correlates (2021) (2)
- Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigen (2020) (2)
- Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancer. (2014) (2)
- Adjuvant Vaccine Therapy in Combination with Radiation for Treatment of Prostate Cancer: Preclinical Validation in a Mouse Model of Prostate Cancer (2008) (2)
- Combination immunotherapy in renal cell carcinoma. (2016) (1)
- Human prostate cancer immune phenotypes after androgen deprivation therapy. (2019) (1)
- A phase II study of muscadine grape skin extract in men with biochemically recurrent prostate cancer. (2017) (1)
- Radiation, Adenosine Signaling, and Immunosuppressive Changes to the Tumor Microenvironment. (2021) (1)
- The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy. (2016) (1)
- IMbassador250: A phase III trial in patients with metastatic castration-resistant prostate cancer (mCRPC) comparing atezolizumab plus enzalutamide vs enzalutamide alone (2018) (1)
- Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma (2019) (1)
- Correlation between innate cytokine levels and progression in men with biochemically recurrent prostate cancer treated with intermittent hormonal therapy. (2019) (1)
- Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): KEYNOTE-991. (2020) (1)
- PDL1 status in muscle-invasive urothelial carcinoma in the context of neoadjuvant cisplatin-based chemotherapy. (2015) (1)
- Non-Invasive Molecular Imaging to Elucidate Mechanisms of Synergy of Immune Checkpoint Blockade and Stereotactic Radiation Therapy (2017) (1)
- Personalized Immune Therapy: A Slippery Fish? (2016) (1)
- Abstract 635: Antigen-specific immune responses in melanoma using stereotactic radiotherapy combined with anti-PD1 checkpoint blockade (2014) (1)
- STARVE-PC: Biomarker-driven phase 2 study of ipilimumab plus nivolumab for AR-V7-expressing metastatic castration-resistant prostate cancer (mCRPC). (2016) (1)
- Absence of coding sequence polymorphism in the serum amyloid P component gene (Sap) in autoimmune New Zealand black mice (1996) (1)
- Abstract 1437: Prostate cancer cells up-regulate PD-L1 in response to pro-inflammatory cytokines. (2013) (1)
- Impact of baseline serum IL-8 on metastatic hormone-sensitive (mHSPC) prostate cancer outcomes in the phase III CHAARTED trial (E3805). (2020) (1)
- Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC). (2017) (1)
- Immune signatures hold prognostic import across solids tumors (2007) (1)
- Systematic Elucidation and Pharmacological Targeting of Tumor-Infiltrating Regulatory T Cell Master Regulators (2022) (1)
- Abstract PO-024: Tumor-specific cell populations in clear cell renal carcinoma associated with clinical outcome identified using single-cell protein activity inference (2020) (1)
- Sipuleucel-T (sip-T)–induced proliferative CD8+ T-cell responses to immunizing and secondary antigens. (2016) (1)
- Immunotherapy for Prostate Cancer—Why Now? (2017) (1)
- Cancer immunity and immunotherapy (2020) (1)
- MP03-01 CLINICAL, PATHOLOGIC AND GENOMIC PROFILES OF EXCEPTIONAL RESPONDERS TO ANTI-PD1 THERAPY IN RENAL CELL CARCINOMA (2016) (1)
- Innate and adaptive inflammation in prostate cancer (2009) (1)
- PD34-08 IMMUNE PROFILING OF TESTICULAR GERM CELL TUMORS REVEALS HIGH EXPRESSION OF PD-L1 AND PD-1 (2016) (1)
- Abstract 812: Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to finasteride in the Prostate Cancer Prevention Trial (2016) (1)
- A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Preliminary clinical data. (2014) (1)
- Graft-Versus-Host Disease in a Murine Model the Pathogenesis of Chronic Sclerodermatous T Cells Is Critical for + STAT3 Signaling in CD4 (2011) (1)
- Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial (2023) (1)
- Immunotherapy for prostate cancer: recent developments and future challenges (2014) (1)
- TH17 cells and early pancreatic tumorigenesis. (2013) (1)
- PD14-06 SIPULEUCEL-T (SIP-T) WITH ENZALUTAMIDE (ENZ) (STRIDE): CLINICAL OUTCOMES IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) BY BASELINE (BL) PROSTATE-SPECIFIC ANTIGEN (PSA) QUARTILES (2018) (1)
- Book Review of “Tumor Immunology and Cancer Vaccines” (2006) (1)
- The Feasibility of Combining Brain Radiation and Fingolimod in Healthy Rodents and in Humans With Newly Diagnosed Glioblastoma (2021) (1)
- B7H1 expression and association with clinical response to sunitinib therapy in patients with metastatic renal cell carcinoma (mRCC). (2013) (1)
- Case Study of Single-cell Protein Activity Based Drug Prediction for Precision Treatment of Cholangiocarcinoma (2022) (1)
- Dendritic Cell Vaccines: Sipuleucel-T and Other Approaches (2013) (1)
- Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab (2015) (1)
- Combining Checkpoint Blockade With Radiation Therapy Results in Tumor and Immunological Responses in an Autochthonous Mouse Model of Lung Cancer (2014) (1)
- Risk Associated With High-Dose Bicalutamide. (2017) (1)
- Phase I/II double-blinded randomized study to determine the tolerability and efficacy of two different doses of lenalidomide (Len) in biochemically relapsed prostate cancer (BRPC) (M0) patients (pts). (2010) (1)
- HomeostasisLAG-3 Regulates Plasmacytoid Dendritic Cell (2009) (0)
- MP28-14 SERUM CYTOKINES AND CHEMOKINES PROFILE AND RISK OF PROSTATE CANCER IN A CASE-CONTROL STUDY AMONG BLACK AND WHITE US VETERAN MEN (2019) (0)
- Immune Checkpoint Upregulation Following Radiation Therapy: Rationale for Combining Radiation Therapy With Multiple Immune Checkpoint Blockades (2013) (0)
- Preoperative Immunotherapy for Prostate Cancer: From Bench to Bedside (2022) (0)
- Abstract 1510: Androgen regulated IL-8 expression in prostate cancer: Insights into tumor cell mediated immunosuppression (2019) (0)
- 17-Dependent AutoimmunityHT 17 Development andHSTAT 3 Signaling in T Cutting Edge : An In Vivo Requirement for (2007) (0)
- The role of PD-1 in human CD8 prostate infiltrating lymphocytes. (66.12) (2011) (0)
- Additional file 19: Figure S10. of A multi-omic analysis of human naĂŻve CD4+ T cells (2015) (0)
- Abstract IA-012: Differential immunological effects of carbon-ion versus photon radiation therapy (2021) (0)
- Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma. (2023) (0)
- LAB-IMMUNOLOGY RESEARCH (2012) (0)
- Cyclic dinucleotides (CDNs) reversed T cells tolerance in anti-tumor immunotherapy (2015) (0)
- MP58-07 TUMOR PD-L1 AND LYMPHOCYTIC INFILTRATE FOXP3 STATUS IN NON-MUSCLE INVASIVE UROTHELIAL CARCINOMA OF BLADDER (NMIBC) (2015) (0)
- Single-Cell RNAseq Analysis Reveals Robust, Anti-PD-1-Mediated Increase of Immune Infiltrate in Metastatic Castration-Sensitive Prostate Cancer (2022) (0)
- The Future of Immunotherapy in Prostate Cancer (2007) (0)
- MP87-15 RANDOMIZED PHASE 2 STUDY EVALUATING OPTIMAL SEQUENCING OF SIPULEUCEL-T AND ANDROGEN DEPRIVATION THERAPY (STAND) IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: PRELIMINARY CLINICAL OUTCOMES (2015) (0)
- Consultation corner. Prostate cancer vaccine offers new direction. (2010) (0)
- Efficacy of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients (pts) with refractory metastatic renal cell carcinoma (mRCC). (2019) (0)
- Abstract LB-251: The checkpoint molecules LAG-3 and PD-1 synergize to maintain tolerance to tumors (2011) (0)
- Infectious tolerance of LAG-3+ regulatory T cells with attenuated T-bet induction (IRC11P.433) (2015) (0)
- Sipuleucel-T (sip-T) to induce cytolytic T lymphocyte (CTL) activity against target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC). (2017) (0)
- Abstract LB-118: A conserved checkpoint molecule signature offers novel targets for tumor specific regulatory T cell manipulation (2018) (0)
- Erratum: B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly induced in anergic CD4+ T cells (Journal of Immunology (2005) 174 (3377-3385)) (2005) (0)
- Abstract 1611: Intravesical BCG induces CD4 T Cell expansion in an immune competent model of bladder cancer (2017) (0)
- Abstract 1312: Transcriptional signatures associated with lack of response to anti-PD-1 therapy in patients with renal cell carcinoma (2015) (0)
- alidomide in Nonmetastatic Biochemically Relapsed state Cancer: Results of a Phase I/II (2010) (0)
- Melanoma and immunotherapy bridge 2015 K1 Immunologic and metabolic consequences of PI3K/AKT/mTOR in melanoma (2016) (0)
- Effect of local therapy on the systemic anti-tumor response in prostate cancer. (2016) (0)
- A single-arm phase II study of ADT with PD-1 blockade and docetaxel in men with metastatic hormone-sensitive prostate cancer. (2020) (0)
- Elucidating the mechanisms of CD8 T cell plasticity (46.1) (2011) (0)
- Abstract PO003: CD38 in the advanced prostate cancer (2021) (0)
- Rate of occult metastases in patients (pts) with biochemically-recurrent prostate cancer (BRPC) from a phase 2 trial of sipuleucel-T and androgen deprivation therapy (STAND). (2017) (0)
- Abstract 3618: Peripheral cytokine profiles and prostate cancer risk in CLUE II. (2013) (0)
- Role of human lymphocyte activation gene 3 in tumor infiltrating lymphocytes (101.12) (2010) (0)
- Cytokine profile of sipuleucel-T (sip-T) in differentiating reactivation of latent immunity from de novo immune responses. (2017) (0)
- Tolerance Induction Phase During the Process of In Vivo T Cells Pass Through an Effector + CD 4 (2003) (0)
- Results of the randomized phase II study of sipuleucel-T (Sip-T) +/- Radium-223 (Ra-223) in men with bone-metastatic castration resistant prostate cancer. (2020) (0)
- Transcription T Cell Function by Coactivating IL-2 Cutting Edge : TCR-Induced NAB 2 Enhances (2006) (0)
- Adoptive transfer of Tc17 CD8 T cells leads to tumor inhibition and anti-tumor response (95.15) (2010) (0)
- A novel approach to mine the Veterans Administration Informatics and Computing Infrastructure (VINCI) allows one to assess the efficacy of cancer therapies: Abiraterone and enzalutamide in Veterans with metastatic prostate cancer (PC). (2018) (0)
- Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor) (2023) (0)
- Phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib) (Cyto-KIK). (2021) (0)
- Immune Checkpoint Inhibition in Renal Cell Carcinoma (2015) (0)
- Abstract 4491: Characterizing long non-coding RNA expression of tumor-infiltrating lymphocytes across solid cancers (2020) (0)
- Abstract PR03: Prophylactic nodal irradiation abrogates the synergy of tumor radiotherapy and immune checkpoint blockade (2017) (0)
- Myeloid Resistance is not Futile: Biomarkers of Immunotherapy in Bladder Cancer (2021) (0)
- Regulation par lymphocytes t (2004) (0)
- Antigen-Specific CD4 T Cells Induce Distinct Transcriptional Profiles in Tumor Recognition and Self-Recognition (2009) (0)
- Gone baby gone - but how? (2012) (0)
- Combining Checkpoint Blockade With Radiation Therapy Results in Tumor and Immunological Responses in an Autochthonous Mouse Model of Lung Cancer : Translational Research (2014) (0)
- Radiation Induces a Dose-Dependent Increase in Immunosuppressive Myeloid Cells in Solid Tumors (2019) (0)
- 837 Depletion of senescent cells reduces growth of mouse melanoma (2019) (0)
- 329 Longitudinal immune profiling reveals unique myeloid and T cell phenotypes associated with spontaneous immunoediting in a novel prostate tumor model (2020) (0)
- 903 Human cancer-associated fibroblast subsets can predict immune checkpoint response in head and neck cancer patients (2021) (0)
- What Was the Prostate? (2021) (0)
- STAT3 Signaling in Donor-Derived CD4 + T-Cells Plays a Critical Role in the Induction of Acute and Chronic GVHD in Murine Models of alloBMT. (2007) (0)
- K 3 Tumor ‐ intrinsic beta ‐ catenin signaling mediates tumor ‐ immune avoidance (2016) (0)
- A phase II study for prostate cancer monitoring using 18F-DCFPyL and blood-based biomarkers. (2019) (0)
- The association of humoral antigen spread (AgS) with cytotoxic T lymphocyte (CTL) activity after sipuleucel-T (sip-T) treatment in two phase II clinical studies: STAMP and STRIDE. (2020) (0)
- The Immunomodulatory Effects of Carbon-Ion Therapy on Solid Tumors (2019) (0)
- Multidisciplinary clinic evaluation changes prostate cancer stage and risk stratification. (2014) (0)
- Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy. (2021) (0)
- 40INIMMUNOTHERAPY FOR PROSTATE CANCER? (2014) (0)
- MP83-20 AN ASSESSMENT OF IMMUNE CHECKPOINT EXPRESSION AMONG PATIENTS WITH NMIBC UNDERGOING INTRAVESICAL BCG: IMPLICATIONS FOR ONGOING RANDOMIZED TRIALS. (2018) (0)
- Abstract 2867: TH17 cells promote early pancreatic tumorigenesis. (2013) (0)
- IMPS-31FOCAL BRAIN RADIATION INDUCES SYSTEMIC LYMPHOPENIA IN MICE (2015) (0)
- T Cell Effector Function + CD8In Vivo Presentation, but Selectively Primes Class I- and Class II-Restricted Epitopes for Glycoprotein 96 Can Chaperone Both MHC (2004) (0)
- Systemic Therapy for Castrat ion-res is tant Prostate Cancer : Novel Agents and New Standards (2011) (0)
- INTRAVESICAL BCG INDUCES CD4+ T CELL EXPANSION BUT NOT ACTIVATION IN A CLINICALLY RELEVANT IMMUNE COMPETENT MODEL OF BLADDER CANCER: MP65‐06 (2017) (0)
- MP28-06 BLACK MEN HAVE HIGHER EXPRESSION OF INFLAMMATORY MARKERS IN PROSTATE BIOPSIES (2019) (0)
- Tumor Immune Microenvironment in Response to Radiotherapy vs BCG in a Murine Model of Bladder Cancer (2020) (0)
- MP21-01 SINGLE CELL TRANSCRIPTIONAL PROFILING OF IMMUNE POPULATIONS WITHIN RENAL CELL CARCINOMA TUMOR MICROENVIRONMENT (2019) (0)
- 1066 The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy (2016) (0)
- The SPARC-1 trial: A phase I study of neoadjuvant combination interleukin-1 beta and PD-1 blockade in localized clear cell renal cell carcinoma. (2021) (0)
- A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer (2019) (0)
- Abstract 1476: Decoding the immunologic landscape of human clear cell renal carcinoma (2019) (0)
- A phase 1 study of alpha-1,3-galactosyltransferase-expressing allogeneic renal cell carcinoma immunotherapy in patients with metastatic renal cell cancer. (2017) (0)
- The impact of clinical stage on renal cell carcinoma outcomes: Implications for neoadjuvant trial design. (2015) (0)
- 49: Blocking the PD-1/PD-L1 axis for cancer therapy (2014) (0)
- Abstract A32: Characterizing patterns of cytokine coexpression with immune checkpoint markers in CD4 and CD8 tumor-infiltrating lymphocytes (2020) (0)
- Additional file 25. of A multi-omic analysis of human naĂŻve CD4+ T cells (2015) (0)
- Abstract 4605: Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial (2015) (0)
- MP67-10 INCREASED INFECTIOUS COMPLICATIONS IN TRANSFUSED PATIENTS AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER (2015) (0)
- Diabetes in the Absence of LAG-3 Cutting Edge: Accelerated Autoimmune (2011) (0)
- in a Murine Model Sclerodermatous Graft-Versus-Host Disease for the Pathogenesis of Chronic T Cells Is Critical + STAT3 Signaling in CD4 (2009) (0)
- ASCO: Presentation Preview on Immunotherapy Approaches for Urological Cancers (2014) (0)
- MOLECULAR SUBTYPE CLASSIFICATION OF N‐METHYL‐N‐NITROSOUREA‐INDUCED UROTHELIAL CANCERS AND EX‐VIVO CULTURED SPHEROIDS IN RATS.: MP48‐19 (2017) (0)
- MP83-08 LOCAL T LYMPHOCYTE SUB-POPULATION RESPONSES TO INTRAVESICAL BCG AND CHEMOTHERAPY IN AN IMMUNE COMPETENT MURINE MODEL OF BLADDER CANCER (2016) (0)
- Régulation des lymphocytes T (2004) (0)
- Single-Cell VIPER Identifies Recurrence-Associated Renal Tumor Macrophages (2021) (0)
- Stereotactic Radiation Combined with 41BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response an a Murine Glioma Model (2014) (0)
- The Emerging Role of Immunotherapy in Castrate-Resistant Prostate Cancer (2014) (0)
- Abstract PO009: Single-cell protein activity inference identifies tumor-enriched macrophages associated with early post-surgical disease recurrence (2021) (0)
- MP4-02 INFLAMMATION IN BENIGN PROSTATE TISSUE AND PROSTATE CANCER IN THE FINASTERIDE ARM OF THE PROSTATE CANCER PREVENTION TRIAL (2015) (0)
- IMPS-20COMBINATION THERAPY WITH ANTI-PD-1, ANTI-TIM-3, AND FOCAL RADIATION RESULTS IN REGRESSION OF MURINE GLIOMAS (2015) (0)
- Combined local and systemic attacks (2018) (0)
- Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma (2016) (0)
- 168 A novel prostate-restricted tumor-associated antigen: a potential therapeutic target (2020) (0)
- Abstract 2968: TH17 cells in early pancreatic tumorigenesis (2012) (0)
- Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer (2018) (0)
- PD28-10 COMBINATORIAL THERAPEUTIC APPROACHES WITH PD-1 INHIBITION IN PROSTATE CANCER (2016) (0)
- Reduced T-bet induction in proliferation- interferon-γ decoupled CD4+ T cells as a mechanism for propagated T cell tolerance (IRC4P.491) (2014) (0)
- 906 Immunogenomic evaluation of clear cell renal carcinoma uncovers HK3 as a myeloid specific metabolic enzyme (2021) (0)
- Tumor Vaccination Combined With Radiation Therapy Mitigates Development and Progression of Metastatic Prostate Cancer: Studies in an Autochthonous Murine Prostate Cancer Model (2013) (0)
- Sipuleucel-T (sip-T) induced lytic CD8+ T cell responses to target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC). (2016) (0)
- Immunological Targeting of Tumor Initiating Prostate Cancer Cells (2014) (0)
- KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response (2023) (0)
- Rapid cycling high dose testosterone (Bipolar Androgen Therapy) as therapy for men with metastatic castrate-resistant prostate cancer (mCRPC) (2016) (0)
- MP66-07 BCG INVOKES SUPERIOR STING-MEDIATED INNATE IMMUNE RESPONSE OVER RADIOTHERAPY IN A CARCINOGEN MURINE MODEL OF UROTHELIAL CANCER (2021) (0)
- Abstract PR-005: Adenosine signaling and radiation-induced immunosuppressive changes to the tumor microenvironment (2021) (0)
- MP13-20 LONG TERM OUTCOMES IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER WHO ARE MISCLASSIFIED AS ACHIEVING A COMPLETE CLINICAL RESPONSE TO NEOADJUVANT CHEMOTHERAPY: HOW COSTLY ARE MISTAKES? (2021) (0)
- VARIANTS IN GENES INVOLVED IN THE IMMUNE RESPONSE AND OXIDATION AND SUBSEQUENT RISK OF PROSTATE CANCER RECURRENCE (2009) (0)
- Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/enzalutamide (Enz) sensitive and resistant metastatic castrate-resistant prostate cancer (mCRPC). (2016) (0)
- Abstract 267: Combining androgen deprivation with immune checkpoint blockade delays the development of castration resistance in a murine model of prostate cancer (2015) (0)
- Deconstructing T Cell Clonal Dynamics in Response to Immune-Checkpoint Blockade (2022) (0)
- Stereotactic Radiation Therapy Combined With Anti-PD-1 Checkpoint Blockade Immunotherapy: Analysis of Clonal Diversity of Induced Antitumor Immune Responses (2015) (0)
- Prostate carcinogenesis: inflammatory storms (2020) (0)
- Harnessing the PD-1 Pathway in Renal Cell Carcinoma: Current Evidence and Future Directions (2014) (0)
- 32: Role of STAT3 Signaling in GVHD and GVL (2008) (0)
- An exploratory study to investigate the immunomodulatory activity of BMS-936558 in patients with metastatic clear-cell renal cell carcinoma. (2012) (0)
- Abstract 2091: Quantitative compositional and spatial analysis of tumor microenvironment (TME) in primary melanoma (2018) (0)
- Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer (2013) (0)
- Abstract 1794: Human cancer associated fibroblast subsets can differentially regulate immunotherapy response in head and neck cancer patients (2021) (0)
- Adoptive transfer of Tc17 CD8 T cells as an approach to elicit a better immune response to vaccination (165.3) (2012) (0)
- Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (0)
- Melanoma and immunotherapy bridge 2015 (2016) (0)
- Abstract IA15: Role of PD-1 and LAG-3 in cancer immunotherapy. (2013) (0)
- T + and Is Highly Induced in Anergic CD4 Structural and Expression Polymorphisms B and T Lymphocyte Attenuator Exhibits (2005) (0)
- Determining molecular mechanisms of Tc17 plasticity in vitro and in vivo (P1414) (2013) (0)
- 47 Effect of local therapy on the systemic anti-tumor response in prostate cancer (2016) (0)
- Relationship between sipuleucel-T (sip-T) cytolytic T lymphocyte (CTL) activity and overall survival (OS) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). (2018) (0)
- Effect of androgen deprivation therapy combined with nivolumab on the systemic antitumor immune response in castration-sensitive prostate cancer. (2020) (0)
- Abstract PO-046: Single-cell profiling of tumor evolution and complex immune infiltrate induced by ADT and PD-1 blockade in metastatic hormone-sensitive prostate cancer (2020) (0)
- Abstract 2837: Combined targeting of antigens expressed in prostate cancer and prostate stem cells using Listeria-based cancer vaccines for the treatment of prostate cancer. (2013) (0)
- Abstract B11: Prognostic biomarkers in stage II-III melanoma (2020) (0)
- 245: Regression of Prostate Cancer in Animals Treated with Donor Lymphocyte Infusion (DLI) and a Cell Based Tumor Vaccine after Conditioning with a Single Dose of Cyclophosphamide (2005) (0)
- Clinical Cancer esearch cer Therapy : Clinical alidomide in Nonmetastatic Biochemically Relapsed state Cancer : Results of a Phase I / II R ble-Blinded , Randomized Study (2010) (0)
- LBP-23-Prognostic Impact of Peritumoral Neutrophil Infiltration on Hepatocellular Carcinoma Recurrence Following Liver Transplantation (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Charles G Drake?
Charles G Drake is affiliated with the following schools:
